TY  - JOUR 
AU  - Jabbour, Elias
AU  - Zugmaier, Gerhard
AU  - Agrawal, Vaibhav
AU  - Martínez Sánchez, Pilar
AU  - Rifón Roca, José J.
AU  - Cassaday, Ryan D.
AU  - Böll, Boris
AU  - Rijneveld, Anita
AU  - Abdul-Hay, Maher
AU  - Huguet, Françoise
AU  - Cluzeau, Thomas
AU  - Tormo Díaz, Mar
AU  - Vucinic, Vladan
AU  - González Campos, José
AU  - Rambaldi, Alessandro
AU  - Schwartz, Stefan
AU  - Berthon, Céline
AU  - Hernández Rivas, Jesús María
AU  - Gordon, Paul R.
AU  - Brüggemann, Monika
AU  - Hamidi, Ali
AU  - Chen, Yuqi
AU  - Wong, Hansen L
AU  - Panwar, Bharat
AU  - Katlinskaya, Yuliya
AU  - Markovic, Ana
AU  - Kantarjian, Hagop
PY  - 2024
SN  - 0361-8609
UR  - http://hdl.handle.net/10366/171846
AB  - [EN]Blinatumomab is a BiTE® (bispecific T-cell engager) molecule that redirects CD3+ T-cells to engage and lyse CD19+ target cells. Here we demonstrate that subcutaneous (SC) blinatumomab can provide high efficacy and greater convenience of...
LA  - eng
PB  - Wiley
KW  - Precursor Cell Lymphoblastic Leukemia-Lymphoma
KW  - Antibodies, Bispecific
KW  - Lymphoma, B-Cell
KW  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
KW  - Antineoplastic Agents
KW  - Adult
KW  - Humans
KW  - Remission Induction
KW  - Pathologic Complete Response
KW  - Acute Disease
KW  - Neoplasm, Residual
KW  - Lymphoma
KW  - Acute Disease
KW  - Precursor Cell Lymphoblastic Leukemia-Lymphoma
KW  - Adult
KW  - Antibodies
KW  - Humans
KW  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
KW  - Remission Induction
KW  - Antineoplastic Agents
TI  - Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia
DO  - 10.1002/ajh.27227
T2  - American Journal of Hematology
VL  - 99
M2  - 586
ER  -